Successful Alternative Administration of Sonidegib in a Patient with Gorlin-Goltz Syndrome and Dysphagia: A Case Report.

INTRODUCTION

Activation of the Hedgehog (HH) pathway is a key factor in the development of basal cell carcinoma.

CASE PRESENTATION: Approved HH pathway inhibitors, like vismodegib and sonidegib, are supplied in capsule form. Patients who suffer from dysphagia may have problems swallowing these medications.

CONCLUSION

This case report describes the successful use of an alternative administration of sonidegib in a patient with Gorlin-Goltz syndrome and dysphagia.